Compare AFBI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AFBI | ACOG |
|---|---|---|
| Founded | 1928 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.6M | 110.4M |
| IPO Year | 2020 | N/A |
| Metric | AFBI | ACOG |
|---|---|---|
| Price | $22.49 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 12.0K | ★ 33.9K |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.42 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | $62.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.86 | $4.50 |
| 52 Week High | $22.50 | $10.88 |
| Indicator | AFBI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 70.58 | 47.54 |
| Support Level | $22.41 | $5.73 |
| Resistance Level | $22.50 | $6.48 |
| Average True Range (ATR) | 0.03 | 0.40 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 75.00 | 50.43 |
Affinity Bancshares Inc is a bank holding company. The bank provides a range of financial services, including checking and savings accounts, certificates of deposit, mortgage, commercial and consumer loans, and money transfer services, operating across parts of Georgia and offering specialized lending such as dental practice and indirect automobile loans across the Southeastern United States. Its business mainly involves accepting public deposits and investing them in real estate and commercial loans, as well as mortgage-backed securities. The company also gathers deposits nationwide through its virtual bank, FitnessBank, and uses additional funding sources such as Federal Home Loan Bank borrowings.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.